Accelerate Diagnostics Statistics
Share Statistics
Accelerate Diagnostics has 25.04M shares outstanding. The number of shares has increased by 64.81% in one year.
Shares Outstanding | 25.04M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 7.39% |
Owned by Institutions (%) | n/a |
Shares Floating | 15.23M |
Failed to Deliver (FTD) Shares | 5.30K |
FTD / Avg. Volume | 8.91% |
Short Selling Information
The latest short interest is 473.08K, so 1.89% of the outstanding shares have been sold short.
Short Interest | 473.08K |
Short % of Shares Out | 1.89% |
Short % of Float | 3.23% |
Short Ratio (days to cover) | 7.77 |
Valuation Ratios
The PE ratio is -0.79 and the forward PE ratio is -1.15.
PE Ratio | -0.79 |
Forward PE | -1.15 |
PS Ratio | 4.06 |
Forward PS | 1.4 |
PB Ratio | -2.46 |
P/FCF Ratio | -1.19 |
PEG Ratio | n/a |
Enterprise Valuation
Accelerate Diagnostics Inc. has an Enterprise Value (EV) of 75.99M.
EV / Earnings | -1.23 |
EV / Sales | 6.3 |
EV / EBITDA | -1.53 |
EV / EBIT | -1.41 |
EV / FCF | -1.84 |
Financial Position
The company has a current ratio of 2.03, with a Debt / Equity ratio of -1.85.
Current Ratio | 2.03 |
Quick Ratio | 1.76 |
Debt / Equity | -1.85 |
Total Debt / Capitalization | 217.4 |
Cash Flow / Debt | -1.09 |
Interest Coverage | -6.98 |
Financial Efficiency
Return on equity (ROE) is 3.1% and return on capital (ROIC) is -283.38%.
Return on Equity (ROE) | 3.1% |
Return on Assets (ROA) | -1.96% |
Return on Capital (ROIC) | -283.38% |
Revenue Per Employee | 89.99K |
Profits Per Employee | -459.84K |
Employee Count | 134 |
Asset Turnover | 0.38 |
Inventory Turnover | 2.87 |
Taxes
Income Tax | 850.00K |
Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -71.15% in the last 52 weeks. The beta is 0.6, so Accelerate Diagnostics 's price volatility has been higher than the market average.
Beta | 0.6 |
52-Week Price Change | -71.15% |
50-Day Moving Average | 1.77 |
200-Day Moving Average | 1.37 |
Relative Strength Index (RSI) | 30.9 |
Average Volume (20 Days) | 59.46K |
Income Statement
In the last 12 months, Accelerate Diagnostics had revenue of $12.06M and earned -$61.62M in profits. Earnings per share was $-4.94.
Revenue | 12.06M |
Gross Profit | 2.55M |
Operating Income | -54.03M |
Net Income | -61.62M |
EBITDA | -49.77M |
EBIT | -54.03M |
Earnings Per Share (EPS) | -4.94 |
Balance Sheet
The company has $12.14M in cash and $39.22M in debt, giving a net cash position of -$27.08M.
Cash & Cash Equivalents | 12.14M |
Total Debt | 39.22M |
Net Cash | -27.08M |
Retained Earnings | -668.86M |
Total Assets | 32.31M |
Working Capital | 9.18M |
Cash Flow
In the last 12 months, operating cash flow was -$40.20M and capital expenditures -$1.03M, giving a free cash flow of -$41.23M.
Operating Cash Flow | -40.20M |
Capital Expenditures | -1.03M |
Free Cash Flow | -41.23M |
FCF Per Share | -3.3 |
Margins
Gross margin is 21.15%, with operating and profit margins of -448.03% and -510.97%.
Gross Margin | 21.15% |
Operating Margin | -448.03% |
Pretax Margin | -503.92% |
Profit Margin | -510.97% |
EBITDA Margin | -412.73% |
EBIT Margin | -448.03% |
FCF Margin | -341.91% |
Dividends & Yields
AXDX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -371.43% |
FCF Yield | -123.79% |
Analyst Forecast
The average price target for AXDX is $1, which is -24.8% lower than the current price. The consensus rating is "Hold".
Price Target | $1 |
Price Target Difference | -24.8% |
Analyst Consensus | Hold |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 12, 2023. It was a backward split with a ratio of 1:10.
Last Split Date | Jul 12, 2023 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -34.07 |
Piotroski F-Score | 4 |